Home › Trial NCT00131989
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
- Trial IDNCT00131989
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorNational Cancer Institute (NCI)
- Enrollment48
- Start date2005-06
- ConditionsAdult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monocytic Leukemia (M5b) · Adult Acute Myeloblastic Leukemia With Maturation (M2)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.